Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial

Affiliations

• ¹ Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU de Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
• ² Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.
• ³ Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, USA.
• ⁴ Institut de Cardiologie, Centre Hospitalier Pitié-Salpêtrière (AP-HP, ACTION Group, University Paris 6), 47 boulevard de l'Hôpital, 75013, Paris, France.
• ⁵ Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain.
• ⁶ Kerckhoff-Klinik, Heart Clinic, Bad Nauheim, Germany.
• ⁷ Norwich Medical School, University of East Anglia, Norwich, UK.
• ⁸ Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
• ⁹ Pfizer Inc., New York, USA.
• ¹⁰ Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU de Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. f.zannad@chru-nancy.fr.